Brian Buntz is a journalist at various esteemed publications, including Medical Design & Outsourcing and MassDevice. He focuses on the intersection of artificial intelligence, healthcare technology, and applied sciences, covering topics such as AI platforms, biotechnology, and digital health. Brian's work has been featured in notable outlets like TED Conferences and Pharmaceutical Processing World.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Brian Buntz's articles primarily focus on the healthcare and pharmaceutical industry, with a strong emphasis on data-driven insights. His coverage suggests an interest in topics such as pharmaceutical innovation, M&A activity, emerging trends in drug approvals, and AI applications within healthcare.
Given his reliance on citing data and press releases, Brian may be interested in pitches that provide comprehensive data analysis or newsworthy findings related to pharmaceuticals, medical research advancements, or trends in healthcare technology. Additionally, he might be open to receiving press releases announcing significant developments within the healthcare and pharmaceutical sectors.
While Brian's geographic focus is not specified, his coverage appears to encompass global perspectives on the healthcare and pharmaceutical industry. Therefore, relevant pitches should consider international implications or broader industry trends rather than focusing solely on specific regional matters unless they have global significance.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Brian Buntz
Over the past several months, SpaceX CEO Elon Musk has been increasingly vocal about putting AI data centers in space. In February, he predicted that, within five years, “we will launch and be operating every year more AI in space than the cumulative total on Earth.” He said then that SpaceX, then still a private…
By: Brian Buntz
Colorized scanning electron micrograph of an HIV-infected T cell. *Image credit: NIAID/NIH*
By: Brian Buntz
Medable’s Pamela Tenaerts says “the CRA still needs to be there,” as she and Tufts’ Ken Getz explain how agents change clinical trial monitoring.
By: Brian Buntz
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.
By: Brian Buntz
BenchBench-Protocol turns published methods and real-world protocol adaptations into expert-reviewed, rubric-scored tasks used to compare frontier and open-weight models. (Image: Benchling)
By: Brian Buntz
Anthropic’s MHS research preview gives Claude and other AI agents a common interface for microscopes, liquid handlers and laboratory robots.
By: Brian Buntz
| Proteolysis Targeting Chimera (PROTAC) drugs have evolved from a promising concept to a clinically validated modality. In May 2026, the U.S.
By: Brian Buntz
The country has transformed considerably since the 1980s. “Back then, we were a coffee-and-banana country,” Morales said. Both the medical device and semiconductor industries have made significant investments. The medical device firm Baxter set up shop in 1987. Intel followed with a landmark $300-million-plus semiconductor assembly-and-test plant investment announced in late 1996 and begun in…
By: Brian Buntz
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.
By: Brian Buntz
This website uses cookies We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services.
